Recombinant Human Glypican 3 / GPC3 Protein, low endotoxin, His tag, 100 µg

Background
Glypican-3 (GPC3) is also known as Intestinal protein OCI-5, GTR2-2, MXR7, which belongs to the glypican family. Glypican 3 / GPC-3 is highly expressed in lung, liver and kidney. Glypican-3 inhibits the dipeptidyl peptidase activity of DPP4. Glypican-3 may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and also may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function.

Source
Recombinant Human Glypican 3 (S359F) Protein, His Tag(GP3-H5223) is expressed from human 293 cells (HEK293). It contains AA Gln 25 - His 559 (Accession # P51654-1(S359F)).
Predicted N-terminus: Gln 25

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 61.7 kDa. The protein migrates as 66-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation and associated via disulfide bonds.

Endotoxin
Less than 0.1 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Extracellular carriers control lipid-dependent secretion, delivery, and activity of WNT morphogens"
de Almeida Magalhaes, Liu, Chan et al
Dev Cell (2023)
(2) "Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation"
Ricci, Ambrosi, Grillini et al
Virchows Arch (2023)
(3) "A role for decorin in improving motor deficits after traumatic brain injury"
Oshima, Siddiqui, Orfila et al
Matrix Biol (2023)
Showing 1-3 of 1981 papers.